Fairvalue-Calculator Fairvalue-Calculator
EN DE

Marker Therapeutics, Inc (MRKR) Fair Value & Analysis

Healthcare · US · Market cap $22.2M

Price$1.31
Fair Value$1.01
Upside-22.9%
Quality95/100
Evidence: Low Range $0.6600 – $1.26

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Marker Therapeutics, Inc (MRKR) currently trades at $1.31, while our model-based Fair Value estimate is $1.01 — implying the stock looks roughly 22.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Marker Therapeutics, Inc (MRKR) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.01 versus a price of $1.31 — about −23% (overvalued). Model-based estimate, not financial advice.
What is the fair value of MRKR?
Our 21-model fair value for Marker Therapeutics, Inc is $1.01 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.31.
What is the quality score of MRKR?
Marker Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.